Trials / Unknown
UnknownNCT05780450
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
Effectiveness of Transcranial Direct Current (tDCS) Treatment in Patients With Persistent Covid Who Present Headaches and Chronic Body Pain.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to verify the efficacy / effectiveness of treatment with transcranial direct therapy (TDCS) in patients with Persistent Covid who present headaches, migraines and chronic pain, such as arthralgias and myalgias. Transcranial Direct Therapy is used in the field of Physiotherapy and Rehabilitation, with results that prove to be effective for the treatment of patients suffering from symptoms such as migraines, headaches, chronic pain, fibromyalgia or chronic neuropathic pain. As can be seen, in the case of patients with Persistent Covid we find several of these symptoms, so it is suggested that, if Transcranial Direct Current Therapy (TDCs) is giving such good results, relieving these symptoms, why can not give such good results and help so much in patients with Persistent Covid, If many of the symptoms are the same, even if the origin or cause is different.
Conditions
- COVID-19
- Long COVID
- Long Covid19
- SARS CoV 2 Infection
- Persistent COVID-19
- Migraine Disorders
- Headaches Chronic
- Cluster Headache
- Arthralgia
- Myalgia
- Chronic Pain
- Post-COVID-19 Syndrome
- Post COVID-19 Condition
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Transcranial Direct Current Therapy (tDCS) | Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential. Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA. The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment. |
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
- First posted
- 2023-03-22
- Last updated
- 2023-06-13
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT05780450. Inclusion in this directory is not an endorsement.